HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease.

AbstractCONTEXT:
Because of a marked increase in the number of requests for antinuclear antibodies, anti-extractable nuclear antigen antibodies, and anti-double-stranded DNA antibodies for the diagnosis of autoimmune rheumatic disease, guidelines have been proposed for their appropriate use.
OBJECTIVE:
To evaluate in terms of clinical efficacy and cost-benefit ratio the outcome of applying a protocol for the diagnosis of autoimmune rheumatic disease.
DESIGN:
A diagnostic protocol for the rational utilization of second-level tests (anti-extractable nuclear antigen antibodies and anti-double-stranded DNA antibodies) was applied at Hospital Polyclinic beginning January 2004. The appropriateness of 685 consecutive requests received at the clinical pathology laboratory from January to June 2004 was assessed. Patients who underwent these laboratory tests were followed up for 12 months after blood sample drawing.
RESULTS:
Introduction of the protocol led to a significant reduction in the number of second-level tests prescribed (27.9% vs 49.5% for anti-extractable nuclear antigen antibodies; 27.5% vs 56.6% for anti-double-stranded DNA antibodies). After the period of observation, none of the 163 patients who had negative results on the first-level test and were asymptomatic, for whom second-level tests had not therefore been performed, were found to have autoimmune rheumatic disease. In 90.5% (77/85) of patients positive for the second-level tests, clinical confirmation of autoimmune rheumatic disease was obtained.
CONCLUSIONS:
Not only did application of the diagnostic protocol reduce the number of second-level tests performed but it also increased their specificity. Our data thus indicate that the use of shared guidelines by clinical and laboratory specialists yields satisfactory results.
AuthorsMarilina Tampoia, Vincenzo Brescia, Antonietta Fontana, Antonietta Zucano, Luigi Francesco Morrone, Nicola Pansini
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 131 Issue 1 Pg. 112-6 (Jan 2007) ISSN: 1543-2165 [Electronic] United States
PMID17227110 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Antibodies, Anti-Idiotypic
  • Antibodies, Antinuclear
  • Antigens, Nuclear
  • DNA
Topics
  • Antibodies, Anti-Idiotypic (blood)
  • Antibodies, Antinuclear (blood)
  • Antigens, Nuclear (immunology)
  • Autoimmune Diseases (blood, diagnosis, immunology)
  • Clinical Protocols
  • Cost-Benefit Analysis
  • DNA (immunology)
  • Humans
  • Immunologic Tests (economics, methods)
  • Practice Guidelines as Topic
  • Rheumatic Diseases (blood, diagnosis, immunology)
  • Sensitivity and Specificity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: